CHICAGO – Already undergoing priority review by the FDA in ovarian cancer (OC), Astrazeneca plc's oral poly-ADP ribose polymerase (PARP) inhibitor olaparib wowed the 50th annual meeting of the American Society of Clinical Oncology (ASCO) with results from a phase II study that paired the compound with the same company's anti-angiogenesis candidate cediranib.